These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35657573)

  • 1. Dacomitinib overcomes afatinib-refractory carcinomatous meningitis in a lung cancer patient harbouring EGFR Ex.19 deletion and G724S mutation; a case report.
    Kunimasa K; Sugimoto N; Tamiya M; Inoue T; Kawamura T; Kanzaki R; Okami J; Nishino K
    Invest New Drugs; 2022 Oct; 40(5):1137-1140. PubMed ID: 35657573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term response in a patient with adenocarcinoma harboring both common and uncommon EGFR mutations.
    Okauchi S; Satoh H
    Invest New Drugs; 2022 Dec; 40(6):1354-1355. PubMed ID: 36152106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies.
    Cortiula F; Pelizzari G; Corvaja C; De Maglio G; Fasola G
    Anticancer Drugs; 2022 Oct; 33(9):960-962. PubMed ID: 35979997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
    Liu J; Jin B; Su H; Qu X; Liu Y
    BMC Cancer; 2019 Jul; 19(1):702. PubMed ID: 31315676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study.
    Cheng WC; Lin CC; Liao WC; Lin YC; Chen CH; Chen HJ; Tu CY; Hsia TC
    BMC Cancer; 2024 Feb; 24(1):228. PubMed ID: 38373960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH; Soo RA
    Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dacomitinib as a retreatment for advanced non-small cell lung cancer patient with an uncommon EGFR mutation.
    Morita A; Hosokawa S; Yamada K; Umeno T; Kano H; Kayatani H; Shiojiri M; Sakugawa M; Bessho A
    Thorac Cancer; 2021 Apr; 12(8):1248-1251. PubMed ID: 33651475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel EGFR exon 21 indel mutation in lung adenocarcinoma and response to dacomitinib: A case report.
    Zhou T; Xiong Q; Hong C; Wang Q; Wang W; Xu C; Cai J;
    Medicine (Baltimore); 2022 Aug; 101(34):e30269. PubMed ID: 36042660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination treatment with bevacizumab plus erlotinib for meningeal carcinomatosis of afatinib-resistant EGFR mutated lung cancer without T790M mutation: a case report.
    Chiba S; Akiyama M; Yakuwa K; Sato H; Hirano K; Utsumi Y; Nagashima H; Sugai T; Maemondo M
    Ann Palliat Med; 2022 Aug; 11(8):2745-2750. PubMed ID: 34806395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential use of EGFR-tyrosine kinase inhibitors based upon EGFR mutation evolution achieves long-term control in a non-small cell lung cancer patient: a case report.
    Jiang Y; Zhang J; Jiang X; Cheng L; Liao X; Li Y; Zhang M; Chen R; Yin T
    Ann Palliat Med; 2021 Jun; 10(6):7051-7056. PubMed ID: 33548986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives.
    Lavacchi D; Mazzoni F; Giaccone G
    Drug Des Devel Ther; 2019; 13():3187-3198. PubMed ID: 31564835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios.
    Kobayashi IS; Viray H; Rangachari D; Kobayashi SS; Costa DB
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944068
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations.
    Wells L; Qin A
    Curr Treat Options Oncol; 2023 Dec; 24(12):1802-1814. PubMed ID: 38095779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab.
    Oashi A; Yasuda H; Kobayashi K; Tani T; Hamamoto J; Masuzawa K; Manabe T; Terai H; Ikemura S; Kawada I; Naoki K; Soejima K
    Mol Cancer Ther; 2019 Sep; 18(9):1593-1601. PubMed ID: 31253648
    [No Abstract]   [Full Text] [Related]  

  • 15. A real-world study of dacomitinib in later-line settings for advanced non-small cell lung cancer patients harboring EGFR mutations.
    Li HS; Zhang JY; Yan X; Xu HY; Hao XZ; Xing PY; Wang Y
    Cancer Med; 2022 Feb; 11(4):1026-1036. PubMed ID: 35023313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited effect of afatinib in a non-small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report.
    Tamura T; Kawakado K; Makimoto G; Nakanishi M; Kuyama S
    Thorac Cancer; 2021 Jun; 12(11):1770-1774. PubMed ID: 33942527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Afatinib, an effective treatment for patient with lung squamous cell carcinoma harboring uncommon EGFR G719A and R776C co-mutations.
    Han C; Ding X; Li M; Luo N; Qi Y; Wang C
    J Cancer Res Clin Oncol; 2022 May; 148(5):1265-1268. PubMed ID: 35230510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea.
    Kim MH; Choi CM; Lee SY; Park CK; Chang YS; Lee KY; Kim SJ; Yang SH; Ryu JS; Lee JE; Lee SY; Park CK; Lee SH; Jang SH; Yoon SH; Jang TW
    Anticancer Res; 2022 Mar; 42(3):1615-1622. PubMed ID: 35220259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: A brief report.
    Peng W; Pu X; Jiang M; Wang J; Li J; Li K; Xu Y; Xu F; Chen B; Wang Q; Cao J; Chen Y; Wu L
    Lung Cancer; 2021 Feb; 152():66-70. PubMed ID: 33352385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.